iRhythm Holdings, Inc.: management transactions · United States · SEC (Form 4)

About iRhythm Holdings, Inc.

iRhythm Holdings, Inc. (ticker: IRTC) is a U.S.-based digital health and medical technology company listed on the NASDAQ in the United States. The company focuses on ambulatory cardiac monitoring and data-driven arrhythmia detection, with a core mission of improving the identification of clinically meaningful heart-rhythm abnormalities, especially atrial fibrillation. Its commercial platform is centered on the Zio® portfolio, which combines wearable ECG sensors, cloud-based data workflows, and AI-enabled analysis to support clinicians in diagnosing and managing cardiac rhythm disorders. iRhythm regularly highlights clinical evidence, product innovation, and broader adoption across cardiology and primary care channels. Founded in San Francisco, iRhythm built its business around a clear clinical gap: traditional 24- to 48-hour Holter monitoring often misses intermittent arrhythmias. The company’s solution extends continuous monitoring for up to 14 days, giving physicians a more complete view of rhythm burden and symptom correlation. This model integrates device hardware, software, technical review, and clinical interpretation, making iRhythm more than a simple sensor vendor. Instead, it operates as a vertically integrated diagnostics platform at the intersection of medical devices, digital workflow, and AI-assisted analysis. From a competitive standpoint, iRhythm holds a differentiated position in the ambulatory ECG market. Its edge is built on a large body of real-world clinical evidence, the convenience of a patch-based form factor, automated data processing, and a long operating history in long-term continuous monitoring. The company competes against other cardiac diagnostics providers, traditional Holter manufacturers, and broader medtech players, but its recurring emphasis on clinical utility and patient adherence supports a strong brand in its niche. The Zio platform is often positioned as a superior alternative to short-duration monitoring when intermittent events are suspected. Geographically, iRhythm still derives most of its business from the United States, while also expanding internationally. A notable recent milestone was the launch of the Zio Long-Term Continuous Monitoring service in Japan in 2025, marking an important step in its overseas commercialization strategy. More recently, iRhythm has continued to publish and present data at major medical congresses in 2025 and 2026, while also announcing an AI collaboration with Lucem Health and reporting progress toward improved operating leverage and cash generation. For investors, iRhythm is best viewed as a growth-oriented healthcare technology company with exposure to reimbursement dynamics, clinical adoption trends, and the continued shift toward longer-duration, AI-enabled cardiac diagnostics.